Drug Profile
Research programme: protein therapeutics - Acceleron
Alternative Names: ACE-1332; ACE-2395; ACE-2536; ACE-2798Latest Information Update: 01 Dec 2021
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Class Antifibrotics; Antineoplastics; Proteins
- Mechanism of Action TGF-beta superfamily protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Fibrosis; Myelofibrosis
Most Recent Events
- 22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Apr 2020 No recent reports of development identified for preclinical development in Fibrosis in USA